CMPS - Rasio utang marang kapitalisasi buku COMPASS Pathways PLC

COMPASS Pathways plc (CMPS) is creating an environment for the treatment of resistant depression, attracting numerous volunteers with FDA support. The company is achieving a breakthrough in psychiatry by developing synthetic molecules for severe conditions. This chart reflects a current share price of 0.70. The business relies on an asset-light strategy, where British R&D centers design the drugs while outsourcing production to external plants, a fact confirmed by the price action.

This ratio measures the share of total liabilities within the equity structure, determining the financial stability and the degree of the business's dependence on external borrowings. Analyzing the ratio of borrowed funds to balance sheet capital allows for an assessment of the ability of COMPASS Pathways plc (CMPS) to finance the strictly controlled logistics of psychotherapeutic drugs without excessive debt load, which is critical for supply chain security.